CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Pexidartinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02734433
NCT02734433Phase 1Completed
CompareCT.gov

A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors

Daiichi Sankyo Co., Ltd.·interventional·Posted Apr 12, 2016·Updated Apr 25, 2022

In Brief

A Phase 1 clinical trial evaluating Pexidartinib for Advanced Solid Tumors. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This is a Phase I, non-randomized, open-label, multiple dose study of pexidartinib in Asian subjects with advanced solid tumors. The study will be conducted in a dose escalation to assess the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and preliminary antitumor activity of pexidartinib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesTaiwan
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 12, 2016
Enrollment StartJun 1, 2016
Primary CompletionJun 13, 2017
Study CompletionMay 28, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.2 years ago

Interventions

Pexidartinibdrug